CRISPR/Cas9 Genome Editing of CCR5 Combined With C46 HIV-1 Fusion Inhibitor for Cellular Resistant to R5 and X4 Tropic HIV-1

Scientists combined an additional anti-HIV-1 therapy, which is C46, a cell membrane-anchored HIV-1 fusion inhibitor with the CRISPR/Cas9 mediated knockout CCR5.